A method for preparing irbesartan condensate
By optimizing the preparation method of irbesartan condensate, using phase transfer catalysts and specific solvent systems, and controlling reaction conditions, the problems of low yield and high energy consumption in existing technologies have been solved, achieving efficient and low-cost industrial production.
Patent Information
- Application Number
- CN202611321710.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2016-06-22
- Publication Date
- 2026-11-17
AI Technical Summary
Existing methods for preparing irbesartan condensates suffer from harsh reaction conditions, low yields, low crystallization temperatures, and high energy consumption, making them unsuitable for large-scale industrial production.
Irbesartan condensate was prepared by reacting irbesartan hydrochloride with biphenyl bromide in a phase transfer catalyst and a specific organic solvent. The reaction conditions were optimized by controlling the temperature and solvent system, followed by vacuum distillation and crystallization.
It achieves high yield (over 96%) preparation, reduces energy consumption, is suitable for industrial production, and is simple to operate and environmentally friendly.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical chemicals, specifically to a method for preparing an irbesartan intermediate, and more specifically to a method for preparing an improved irbesartan condensate. Technical Background
[0002] Irbesartan is a competitive antagonist of the angiotensin II (AT1) receptor, developed by the French company Sanofi. It lowers blood pressure by blocking type I angiotensin II (AT-II) receptors. Irbesartan was first marketed in the UK in 1997 for the clinical treatment of hypertension.
[0003]
[0004] Irbesartan condensate is a key intermediate in the preparation of irbesartan, and its chemical name is 2-cyano-4'-((2-butyl-4-one-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-1,1'-biphenyl. There are two main methods for preparing irbesartan condensate:
[0005] Patents US 6162922 and CN 102898420 report a method for reacting irbesartan cyclic compound hydrochloride with biphenyl bromide in the presence of a phase transfer catalyst, using dichloromethane as the reaction solvent and sodium hydroxide as the base, to generate irbesartan condensate. This preparation method suffers from drawbacks such as low yield, low crystallization temperature, high energy consumption, and the need for mixed solvents, which are unfavorable for the industrial production of irbesartan.
[0006]
[0007] Patents CN 1415614 and CN 102491970 report the preparation of irbesartan condensates from irbesartan cyclates and biphenyl bromide. This method requires the use of a transition metal catalyst (copper salt) or a demanding anhydrous reaction system (NaH / DMF), which is not conducive to large-scale industrial production.
[0008]
[0009] This invention provides a method for preparing irbesartan condensate, which overcomes the shortcomings of the prior art, such as harsh reaction conditions, low yield, low crystallization temperature, and high energy consumption. It has the advantages of mild reaction conditions, low crystallization energy consumption, and high product yield, which is conducive to large-scale industrial production. Summary of the Invention
[0010] The purpose of this invention is to provide a method for preparing irbesartan condensates, the method comprising the following steps:
[0011] 1) Add a phase transfer catalyst and organic solvent A or a mixture of organic solvent A and water to irbesartan cyclase hydrochloride and biphenyl bromide, and add sodium hydroxide solution at -5 to 15°C; heat the solution to 20 to 50°C and stir for 2 to 10 hours. After the reaction is complete, separate the aqueous layer to obtain an irbesartan condensate solution;
[0012] 2) The irbesartan condensate solution prepared above is subjected to vacuum distillation to remove solvent A or part of solvent A at 25-80°C. Organic solvent B is added to the residue, and the mixture is stirred at 0-40°C for 1-12 hours to crystallize. The mixture is then filtered and dried to obtain the irbesartan condensate.
[0013] The reaction formulas involved in the above preparation method are as follows:
[0014]
[0015] Solvent A used in step 1) is selected from C2-C6 acetates, C1-C3 haloalkanes, and C7-C6 alkyl esters. 10 An aromatic compound or any one thereof mixed with water as a solvent. Solvent A is preferably ethyl acetate, isopropyl acetate, n-butyl acetate, sec-butyl acetate, tert-butyl acetate, toluene, xylene, dichloromethane or any one thereof mixed with water; the volume ratio of the organic solvent A to the mass of the added cyclic compound hydrochloride is 2.0 to 20.0:1.0 (v / w), preferably 4.0 to 10.0:1.0 (v / w).
[0016] In step 1), the molar ratio of irbesartan cyclic compound hydrochloride to biphenyl bromide is 1.0:0.85-1.20, preferably 1.0:0.95-1.05.
[0017] The phase transfer catalyst used in step 1) is a quaternary ammonium salt, preferably tetrabutylammonium bromide or tetrabutylammonium chloride; the amount of phase transfer catalyst used is 0.3% to 10.0% of the mass of the cyclized hydrochloride, preferably 0.5% to 3.0%.
[0018] In step 1), the preferred temperature range for adding sodium hydroxide is 0–15°C, more preferably 0–10°C; the preferred temperature range for the reaction of the liquid is 20–40°C, more preferably 25–35°C.
[0019] The mass fraction of the sodium hydroxide solution added in step 1) is 10% to 45%, preferably 25% to 35%; the molar ratio of the amount of sodium hydroxide added to the cyclic compound hydrochloride is 2.0 to 10.0:1.0, preferably 3.0 to 6.0:1.0.
[0020] The organic solvent B used in step 2) is selected from petroleum ether, C5-C645, etc. 10 Chain alkanes or C5-C10 The cyclic alkanes are preferably petroleum ether, n-hexane, cyclohexane, or n-heptane with a boiling range of 60-90℃; the volume ratio of organic solvent B to the mass of the added cyclic compound hydrochloride is 2.0-20.0:1.0 (v / w), preferably 3.0-15.0:1.0 (v / w).
[0021] In step 2), the volume of solvent A distilled out is such that the ratio of the volume of the remaining solvent to the mass of the added cyclic compound hydrochloride is 0–12.0:1.0 (v / w), preferably 0–6.0:1.0 (v / w).
[0022] In step 2), the preferred temperature range for vacuum distillation of solvent A is 50–80°C; the preferred temperature range for crystallization of the condensate is 20–35°C.
[0023] This invention provides a method for preparing irbesartan condensates, which has low cost and a yield of up to 96%. At the same time, the preparation method of this invention is simple to operate, environmentally friendly, and suitable for industrial production. Detailed Implementation
[0024] The present invention will be further described below with reference to embodiments, but these examples do not constitute any limitation on the present invention.
[0025] Example 1:
[0026] 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.0 g of tetrabutylammonium bromide, and 210 mL of dichloromethane were added to a 250 mL three-necked flask, followed by the addition of 75 g of 30% sodium hydroxide solution at 5 °C. The mixture was heated to 30 °C and stirred for 6 hours. After the reaction was complete, the aqueous layer was separated. The solvent in the organic layer was removed under reduced pressure at 50–60 °C. The residue was then added to 200 mL of n-hexane and stirred at 25 °C for 5 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 54.2 g of irbesartan condensate, with a yield of 92.6% and an HPLC purity of 98.8%.
[0027] Example 2:
[0028] 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.0 g of tetrabutylammonium bromide, and 120 mL of isopropyl acetate were added to a 250 mL three-necked flask. 120 g of 30% sodium hydroxide solution was added at 5°C. The mixture was heated to 30°C and stirred for 6 hours. After the reaction was complete, the aqueous layer was separated. The solvent in the organic layer was removed under reduced pressure at 50–60°C. 150 mL of n-heptane was added to the residue, and the mixture was stirred at 25°C for 6 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 56.1 g of irbesartan condensate, with a yield of 96.0% and an HPLC purity of 98.5%.
[0029] Example 3:
[0030] 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.0 g of tetrabutylammonium bromide, and 340 mL of isopropyl acetate were added to a 250 mL three-necked flask. 75 g of 30% sodium hydroxide solution was added at 5°C. The mixture was heated to 30°C and stirred for 6 hours. After the reaction was complete, the aqueous layer was separated. The organic layer was evaporated under reduced pressure at 50–60°C until 50 mL of isopropyl acetate remained. 200 mL of n-heptane was added to the residue, and the mixture was stirred at 25–30°C for 5 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 52.9 g of irbesartan condensate, with a yield of 90.5% and an HPLC purity of 99.4%.
[0031] Example 4:
[0032] 35.0 g of irbesartan cyclic compound hydrochloride, 39.2 g of biphenyl bromide, 1.0 g of tetrabutylammonium bromide, and 120 mL of isopropyl acetate were added to a 250 mL three-necked flask, followed by the addition of 75 g of 30% sodium hydroxide solution at 5 °C. The mixture was heated to 30 °C and stirred for 6 hours. After the reaction was complete, the aqueous layer was separated. The organic layer was evaporated under reduced pressure at 50–60 °C to remove the solvent. The residue was then mixed with 350 mL of n-heptane and stirred at 25 °C for 5 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 52.0 g of irbesartan condensate, with a yield of 89.2% and an HPLC purity of 98.9%.
[0033] Example 5:
[0034] 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.0 g of tetrabutylammonium bromide, and 150 mL of isopropyl acetate were added to a 250 mL three-necked flask. 120 g of 30% sodium hydroxide solution was added at 5°C. The mixture was heated to 30°C and stirred for 6 hours. After the reaction was complete, the aqueous layer was separated. The solvent in the organic layer was evaporated under reduced pressure at 50–60°C. 525 mL of cyclohexane was added to the residue, and the mixture was stirred at 25°C for 5 hours to crystallize. The mixture was filtered, and the filter cake was dried under vacuum to give 51.1 g of irbesartan condensate, with a yield of 87.6% and an HPLC purity of 99.1%.
[0035] Example 6:
[0036] 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.0 g of tetrabutylammonium bromide, and 150 mL of toluene were added to a 250 mL three-necked flask. 100 g of 30% sodium hydroxide solution was added at 10 °C. The mixture was heated to 30 °C and stirred for 6 hours. After the reaction was complete, the aqueous layer was separated. The solvent in the organic layer was removed under reduced pressure at 60–70 °C. 150 mL of n-heptane was added to the residue, and the mixture was stirred at 25 °C for 6 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 54.5 g of irbesartan condensate, with a yield of 93.2% and an HPLC purity of 98.7%.
[0037] Example 7:
[0038] 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.0 g of tetrabutylammonium bromide, and 120 mL of isopropyl acetate were added to a 250 mL three-necked flask. 75 g of 30% sodium hydroxide solution was added at 10 °C. The mixture was heated to 35 °C and stirred for 4 hours. After the reaction was complete, the aqueous layer was separated. The solvent in the organic layer was removed under reduced pressure at 50–60 °C. The residue was added to 250 mL of petroleum ether (boiling range 60–90 °C), and the mixture was stirred at 25 °C for 6 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 52.9 g of irbesartan condensate, with a yield of 90.7% and an HPLC purity of 98.6%.
[0039] Example 8:
[0040] In a 250 mL three-necked flask, 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.0 g of tetrabutylammonium bromide, and 120 mL of ethyl acetate were added. 75 g of 30% sodium hydroxide solution was added at 5 °C. The mixture was heated to 30 °C and stirred for 5 hours until the reactants were completely reacted. The aqueous layer was separated. The solvent in the organic layer was evaporated under reduced pressure at 50–60 °C. 150 mL of n-heptane was added to the residue, and the mixture was stirred at 25 °C for 6 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 53.3 g of irbesartan condensate, with a yield of 91.2% and an HPLC purity of 98.5%.
[0041] Example 9:
[0042] 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.5 g of tetrabutylammonium chloride, and 500 mL of isopropyl acetate were added to a 250 mL three-necked flask. 75 g of 30% sodium hydroxide solution was added at 5°C. The mixture was heated to 30°C and stirred for 6 hours. After the reaction was complete, the aqueous layer was separated. The organic layer was evaporated under reduced pressure at 50–60°C until 350 mL of isopropyl acetate remained. 350 mL of n-heptane was added to the residue, and the mixture was stirred at 25°C for 6 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 51.7 g of irbesartan condensate, with a yield of 88.6% and an HPLC purity of 99.3%.
[0043] Example 10:
[0044] 35.0 g of irbesartan cyclic compound hydrochloride, 41.0 g of biphenyl bromide, 1.5 g of tetrabutylammonium chloride, and 350 mL of tert-butyl acetate were added to a 250 mL three-necked flask. 75 g of 30% sodium hydroxide solution was added at 5°C. The mixture was heated to 30°C and stirred for 6 hours. After the reaction was complete, the aqueous layer was separated. The organic layer was evaporated under reduced pressure at 50–60°C until 210 mL of tert-butyl acetate remained. 250 mL of n-heptane was added to the residue, and the mixture was stirred at 20°C for 6 hours to induce crystallization. The mixture was filtered, and the filter cake was dried under vacuum to obtain 53.2 g of irbesartan condensate, with a yield of 91.0% and an HPLC purity of 98.8%.
Claims
1. A method for preparing an irbesartan condensate, characterized in that... The method is as follows: 1) Add a phase transfer catalyst, organic solvent A or a mixture of organic solvent A and water to irbesartan cyclase hydrochloride and biphenyl bromide, and add sodium hydroxide solution; after stirring the reaction, separate the aqueous layer to obtain irbesartan condensate solution; 2) The solvent A is removed from the irbesartan condensate solution prepared above by vacuum evaporation or partial removal of solvent A. Organic solvent B is added to the residue, stirred to induce crystallization, filtered and dried to obtain the irbesartan condensate. Solvent A is selected from C7~C6. 10 Aromatic compounds or any one thereof mixed with water as a solvent; organic solvent B is selected from petroleum ether, C5~C 10 Chain alkanes or C5~C 10 cyclic alkanes, the reaction formula is as follows:
2. The method for preparing the irbesartan condensate as described in claim 1, characterized in that... In step 1), the molar ratio of irbesartan cyclic compound hydrochloride to biphenyl bromide is 1.0:0.85~1.20, preferably 1.0:0.95~1.
05.
3. The method for preparing the irbesartan condensate as described in claim 1, characterized in that... The phase transfer catalyst used in step 1) is a quaternary ammonium salt, preferably tetrabutylammonium bromide or tetrabutylammonium chloride; the amount of phase transfer catalyst used is 0.3% to 10.0% of the mass of the cyclized hydrochloride, preferably 0.5% to 3.0%.
4. The method for preparing the irbesartan condensate as described in claim 1, characterized in that... The solvent A used in step 1) is toluene, xylene or any one of them mixed with water; the volume ratio of the organic solvent A to the mass of the added cyclic compound hydrochloride is 2.0~20.0:1.0 (v / w), preferably 4.0~10.0:1.0 (v / w).
5. The method for preparing the irbesartan condensate as described in claim 1, characterized in that... In step 1), the temperature range for adding sodium hydroxide is -5 to 15°C, preferably 0 to 15°C, and more preferably 0 to 10°C; the temperature range for the reaction of the liquid is 20 to 50°C, preferably 20 to 40°C, and more preferably 25 to 35°C.
6. The method for preparing the irbesartan condensate as described in claim 1, characterized in that... The mass fraction of the sodium hydroxide solution added in step 1) is 10%~45%, preferably 25%~35%; the molar ratio of the amount of sodium hydroxide added to the cyclic compound hydrochloride is 2.0~10.0:1.0, preferably 3.0~6.0:1.
0.
7. The method for preparing the irbesartan condensate as described in claim 1, characterized in that... In step 2), the organic solvent B is petroleum ether, n-hexane, cyclohexane, or n-heptane with a boiling range of 60-90℃; the volume ratio of organic solvent B to the mass of the added cyclic compound hydrochloride is 2.0~20.0:1.0 (v / w), preferably 3.0~15.0:1.0 (v / w).
8. The method for preparing the irbesartan condensate as described in claim 1, characterized in that... In step 2), the volume of solvent A distilled out is such that the ratio of the volume of the remaining solvent to the mass of the added cyclic compound hydrochloride is 0~12.0:1.0 (v / w), preferably 0~6.0:1.0 (v / w).
9. The method for preparing the irbesartan condensate as described in claim 1, characterized in that... In step 2), the temperature range for vacuum distillation of solvent A is 25~80℃, preferably 50~80℃; the crystallization temperature range for the condensate is 0~40℃, preferably 20~35℃; and the stirring crystallization time is 2-10 hours.
Citation Information
Patent Citations
Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
US6162922A
